ReviewTheranostics2024
Engineered bacterial outer membrane vesicles: a versatile bacteria-based weapon against gastrointestinal tumors.
Review in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Review
- From Cell-Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery.Advanced healthcare materials · 2026Review
- [Preparation of HLYVSPW peptide-displaying outer membrane vesicles and validation of their in vitro targeting effects on triple-negative breast cancer cells].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Article
- Autonomous intranasal delivery systems for central nervous system therapeutics.Experimental & molecular medicine · 2026Review
- Article
- Bacterial Outer Membrane Vesicles: Research Advances from Biogenesis Mechanisms to Engineered Applications.Membranes · 2026Review
- Stepwise mitochondria-targeted photodynamic immunotherapy enabled by an outer membrane vesicles-based nanoplatform for synergistic tumor ablation and immune reprogramming.Smart molecules : open access · 2026Article
- Biomineralized outer membrane vesicles for synergistic immuno-photodynamic therapy of oral squamous cell carcinoma.International journal of pharmaceutics: X · 2026Article
- The gut-liver/bile axis: Gut microbiota and bacterial extracellular vesicles remodeling hepatobiliary pathogenesis.iScience · 2026Review
- The Role of Oral Pathobionts' Outer Membrane Vesicles in Cancer Pathology and Therapeutic Development.Cells · 2026Review
- Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Outer membrane vesicles: Versatile nanocarriers for therapeutic delivery and immune modulation.Acta pharmaceutica Sinica. B · 2026Review
- Bacterial Membrane Vesicles: Biogenesis, Functions, and Emerging Biotechnological Applications.Microorganisms · 2026Review
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- [Research progress on the mechanism and potential applications of gut microbiota-derived extracellular vesicles in ischemic stroke].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Review
- Bacterial outer membrane vesicles: a smart platform for biomedical applications.Cell communication and signaling : CCS · 2026Review
- Pleiotropic effects of signal peptide peptidase A (Frontiers in veterinary science · 2026Article
- Gut microbiota-immune crosstalk in osteoarthritis: pathogenic mechanisms and emerging therapeutic opportunities.Frontiers in microbiology · 2026Review
- Engineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects.Extracellular vesicles and circulating nucleic acids · 2026Review
- From Mechanism to Clinic: Engineered Bacteria-Nanomaterial Hybrid Systems for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outer membrane vesicles (OMVs) are nanoscale lipid bilayer structures released by gram-negative bacteria. They share membrane composition and properties with their originating cells, making them adept at traversing cellular barriers. These OMVs have demonstrated exceptional membrane stability, immunogenicity, safety, penetration, and tumor-targeting properties, which have been leveraged in developing vaccines and drug delivery systems. Recent research efforts have focused on engineering OMVs to increase production yield, reduce cytotoxicity, and improve the safety and efficacy of treatment. Notably, gastrointestinal (GI) tumors have proven resistant to several traditional oncological treatment strategies, including chemotherapy, radiotherapy, and targeted therapy. Although immune checkpoint inhibitors have demonstrated efficacy in some patients, their usage as monotherapy remains limited by tumor heterogeneity and individual variability. The immunogenic and modifiable nature of OMVs makes them an ideal design platform for the individualized treatment of GI tumors. OMV-based therapy enables combination therapy and optimization of anti-tumor effects. This review comprehensively summarizes recent advances in OMV engineering for GI tumor therapy and discusses the challenges in the clinical translation of emerging OMV-based anti-tumor therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.